Tectonic Therapeutic (NASDAQ:TECX) Lifted to “Strong-Buy” at Leerink Partnrs

Leerink Partnrs upgraded shares of Tectonic Therapeutic (NASDAQ:TECX) to a strong-buy rating in a research note issued to investors on Wednesday, Zacks.com reports. Leerink Partnrs also issued estimates for Tectonic Therapeutic’s Q3 2024 earnings at ($0.50) EPS, Q4 2024 earnings at ($0.53) EPS, FY2024 earnings at ($3.49) EPS, Q1 2025 earnings at ($0.73) EPS, Q2 2025 earnings at ($0.72) EPS, Q3 2025 earnings at ($0.90) EPS, Q4 2025 earnings at ($1.01) EPS, FY2025 earnings at ($3.36) EPS, FY2026 earnings at ($2.62) EPS, FY2027 earnings at ($3.82) EPS and FY2028 earnings at ($3.99) EPS.

TECX has been the topic of several other research reports. SVB Leerink began coverage on shares of Tectonic Therapeutic in a research note on Wednesday. They issued an outperform rating and a $49.00 price objective on the stock. TD Cowen assumed coverage on shares of Tectonic Therapeutic in a research report on Monday, June 24th. They issued a buy rating on the stock. Finally, Piper Sandler started coverage on Tectonic Therapeutic in a report on Wednesday, June 26th. They issued an overweight rating and a $76.00 price target on the stock.

Tectonic Therapeutic Price Performance

Shares of NASDAQ TECX opened at $17.64 on Wednesday. Tectonic Therapeutic has a 1 year low of $12.12 and a 1 year high of $19.80. The firm has a market cap of $791.86 million, a price-to-earnings ratio of 25.57 and a beta of 2.63.

Tectonic Therapeutic (NASDAQ:TECX) last announced its earnings results on Thursday, May 9th. The company reported ($0.15) earnings per share for the quarter. Equities research analysts forecast that Tectonic Therapeutic will post -4.24 earnings per share for the current year.

About Tectonic Therapeutic

Avrobio, Inc is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc is based in MA, United States.